Applying Recent Advances in PET to Clinical Practice

Focusing on recent developments in PET agents and technologies that are changing the practice of nuclear medicine and diagnostic imaging, this Online Course emphasizes key indications, common scenarios, and clinical applications.

Earn credit at your own pace through October 25, 2023 and continue to access your videos until October 26, 2030. See below for learning outcomes and a list of modules and individual lectures.

This course package offers 4 CME Credits following completion of an online test.

ARRS Member price: $295
ARRS In-Training Member price: $149
Nonmember price: $545

 

View the Sample Recording

Learning Outcomes and Lectures

After completing this course, the learner should be able to:

  • Discuss the role of PET in prostate cancer and neuroendocrine tumor diagnosis and therapy
  • Apply the appropriate PET response criteria in to oncologic studies
  • Explain the use of PET agents for the assessment of suspected Alzheimer’s disease and other cognitive disorders
  • Outline best practices and imaging findings in PET/CT relevant to COVID-19
  • Predict the potential clinical applications of FDOPA-PET for cancer and brain imaging

Module 1

  • Prostate Cancer—S. Galgano
  • Neuroendocrine Tumors—A. Goenka
  • PET Response Criteria—H. Jacene

Module 2

  • Cognitive Disorders—P. Kuo
  • PET/MRI—G. Johnson
  • FDOPA—J. McConathy
  • PET in the COVID-19 Era—E. Rohren
     

The American Roentgen Ray Society (ARRS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

The ARRS designates this enduring activity for a maximum of 4.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

View the ARRS Return Policy.